Trial · NCT02007278
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Glycemic Variability Measured by Mean Amplitude of Glucose Excursions (MAGE) | Vildagliptin and Metformin | 6.68 | Standard Deviation 1.48 | mg/dL | |
| Glycemic Variability Measured by Mean Amplitude of Glucose Excursions (MAGE) | Glimepiride and Metformin | 6.23 | Standard Deviation 1.08 | mg/dL | |
| Glycemic Variability Measured by Continuous Overlapping Net Glycemic Action (CONGA) | Vildagliptin and Metformin | 2.92 | Standard Deviation 0.93 | mg/dL | |
| Glycemic Variability Measured by Continuous Overlapping Net Glycemic Action (CONGA) | Glimepiride and Metformin | 3.01 | Standard Deviation 1.10 | mg/dL | |
| Glycemic Variability Measured by Total Standard Deviation (TSD) | Vildagliptin and Metformin | 1.36 | Standard Deviation 0.40 | mg/dL | |
| Glycemic Variability Measured by Total Standard Deviation (TSD) | Glimepiride and Metformin | 1.40 | Standard Deviation 0.42 | mg/dL | |
| Percentage of Patients Who Achieved a Decrease Equal to or Greater Than 0.3% in Value of HbA1c at Week 12 | Vildagliptin and Metformin | 100.0 | percentage of patients | ||
| Percentage of Patients Who Achieved a Decrease Equal to or Greater Than 0.3% in Value of HbA1c at Week 12 | Glimepiride and Metformin | 100.0 | percentage of patients | ||
| Change in HbA1c at Week 12 of Treatment in Comparison to HbA1c at Baseline | Vildagliptin and Metformin | 1.92 | Standard Deviation 1.1 | Percentage of glycosylated haemoglobin | |
| Change in HbA1c at Week 12 of Treatment in Comparison to HbA1c at Baseline | Glimepiride and Metformin | 2.28 | Standard Deviation 0.79 | Percentage of glycosylated haemoglobin | |
| Number of Patients With Incidence of Hypoglycemia | Vildagliptin and Metformin | 1 | Patients | ||
| Number of Patients With Incidence of Hypoglycemia | Glimepiride and Metformin | 4 | Patients | ||
| Mean Amplitude of Glycemic Excursions (MAGE) for Patients With Hypoglycemia Incidence After 12 Weeks of Treatment | Vildagliptin and Metformin | 5.23 | Standard Deviation NA | mg/dL | |
| Mean Amplitude of Glycemic Excursions (MAGE) for Patients With Hypoglycemia Incidence After 12 Weeks of Treatment | Glimepiride and Metformin | 5.53 | Standard Deviation 0.82 | mg/dL | |
| Number of Patients With Any Adverse Events, Serious Adverse Events and Death | Vildagliptin and Metformin | Any adverse events (serious and non-serious) | 9 | Patients | |
| Number of Patients With Any Adverse Events, Serious Adverse Events and Death | Glimepiride and Metformin | Any adverse events (serious and non-serious) | 13 | Patients | |
| Number of Patients With Any Adverse Events, Serious Adverse Events and Death | Vildagliptin and Metformin | Serious Adverse Events | 0 | Patients | |
| Number of Patients With Any Adverse Events, Serious Adverse Events and Death | Glimepiride and Metformin | Serious Adverse Events | 1 | Patients | |
| Number of Patients With Any Adverse Events, Serious Adverse Events and Death | Vildagliptin and Metformin | Death | 0 | Patients | |
| Number of Patients With Any Adverse Events, Serious Adverse Events and Death | Glimepiride and Metformin | Death | 0 | Patients |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02007278/results